Arbutus Biopharma identifies new PD-L1 antagonists
Oct. 28, 2022
Arbutus Biopharma Corp. has described programmed cell death 1 ligand 1 (PD-L1) antagonists reported to be useful for the treatment of cancer, hepatitis B and hepatitis D viral infection.